Author:
Costa Clemens Sue Ann,Weckx Lily,Clemens Ralf,Almeida Mendes Ana Verena,Ramos Souza Alessandra,Silveira Mariana B V,da Guarda Suzete Nascimento Farias,de Nobrega Maristela Miyamoto,de Moraes Pinto Maria Isabel,Gonzalez Isabela G S,Salvador Natalia,Franco Marilia Miranda,de Avila Mendonça Renata Navis,Queiroz Oliveira Isabelle Silva,de Freitas Souza Bruno Solano,Fraga Mayara,Aley Parvinder,Bibi Sagida,Cantrell Liberty,Dejnirattisai Wanwisa,Liu Xinxue,Mongkolsapaya Juthathip,Supasa Piyada,Screaton Gavin R,Lambe Teresa,Voysey Merryn,Pollard Andrew J,Bittaye Mustapha,Woods Danielle,Davies Sophie,Smith Holly,Ulaszewska Marta,Sanders Helen,Mabette Reece,Vernon Sophie,Valliji Zara,Mead Gracie,Tejpal Chitra,Park Juyeon,Beveridge Amy,Eldawi Ahmed,Felle Sally,Fraga Mayara,Muniz Martins Thaiane,Martins Medrado Claudia Loureiro,de Arruda Cordeiro Matos Laiana Januse
Funder
NIHR Oxford Biomedical Research Centre
Reference17 articles.
1. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey;Tanriover;Lancet,2021
2. Efficacy and safety of a COVID-19 inactivated vaccine in healthcare professionals in Brazil: the PROFISCOV study;Palacios;SSRN,2021
3. Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile;Jara;N Engl J Med,2021
4. Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of COVID-19 in Brazil: test negative case-control study;Ranzani;BMJ,2021
5. A booster dose is immunogenic and will be needed for older adults who have completed two doses vaccination with CoronaVac: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial;Li;medRxiv,2021